News

Aastrom Biosciences has reported revenues of $69,000 consisting of product sales for the fourth quarter ended June 30,2009, a decrease when compared to $149,000 for the fourth quarter

Addex Pharmaceuticals’ (Addex) ADX10059 has demonstrated significant potential in a non-human primate model of Parkinson’s disease levodopa induced dyskinesia (PD-LID). ADX10059 is an allosteric inhibitor – a negative

Aeolus Pharmaceuticals has initiated second study in mice, to determine the optimal length of treatment with AEOL 10150 when used as a countermeasure to Acute Radiation Syndrome (ARS)

Protalix Biotherapeutics (Protalix) has completed its pivotal phase III trial for prGCD, the company’s proprietary plant-cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease.

Regeneron has completed patient enrollment in two randomised, double-masked, phase 3 clinical trials evaluating VEGF Trap-Eye in the treatment of the neovascular form of age-related macular degeneration (wet

Tobira Therapeutics (Tobira) has reported pharmacokinetic data and results from a double-blind, placebo-controlled, multiple-dose randomised study of TBR-652 in sixty healthy volunteers. TBR-652, a CCR5 antagonist under investigation

Vical has announced the results from a four-month interim analysis in an ongoing phase 2 trial for TransVax therapeutic cytomegalovirus (CMV) DNA vaccine. The results were presented at

OctoPlus has signed a pharmaceutical development and manufacturing contract with Axentis Pharma. The undisclosed contract value contributes to OctoPlus’ annual revenues, for which the company reiterates its guidance

Merck has provided new data from a phase IIB clinical study of odanacatib, oral, once-weekly investigational treatment for osteoporosis. The data showed that when stopping treatment after two